Pharmacokinetics of enoxaparin in COVID-19 critically ill patients.

ABSTRACT:

Background

In intensive-care unit (ICU) patients, pathophysiological changes may affect the pharmacokinetics of enoxaparin and result in underdosing.

Objectives

To develop a pharmacokinetic model of enoxaparin to predict the time-exposure profiles of various thromboprophylactic regimens in COVID-19 ICU-patients.

Methods

This was a retrospective study in ICUs of two French hospitals. Anti-Xa activities from consecutive patients with laboratory-confirmed SARS-CoV-2 infection treated with enoxaparin for the prevention or the treatment of venous thrombosis were used to develop a population pharmacokinetic model using non-linear mixed effects techniques. Monte Carlo simulations were then performed to predict enoxaparin exposure at steady-state after three days of administr

SUBMITTER: Zufferey PJ 

PROVIDER: S-EPMC8294601 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature